A novel combination of CDK4/6 and PI3K inhibitors exhibits highly synergistic activity and translational potential in Ewing sarcoma.
Helen F. Gloege, Maria Ana Isabel C. De Los Santos, Advaita Chakraborty, Madhav Chadha, Alejandra E. Aguilar-Quintero, Min Shen, Caleb Heaslip, Sarah Finstuen-Magro, Brigit McDannell, Mohammad Tanhaemami, Stephanie C. Meyer, Kelly S. Klega, Yaqin Zhang, David Stephen Shulman, Steven G. DuBois, , Brian D. Crompton
This paper identifies a synergistic combination of CDK4/6 and PI3K inhibitors that shows strong anti-Ewing sarcoma activity and improved survival in a xenograft model.
Translational Oncology · Jun 18, 2026Peer-reviewedCancer Biology